Abstract:Pulmonary arterial hypertension (PAH) is a progressive fatal disease with a complex pathogenic mechanism. Recent studies report that nearly 60% of patients with PAH have metabolic syndrome (MS). Unrecognized glucose intolerance and insulin resistance were also shown to be common in PAH, raising the possibility that metabolic disease predisposes to PAH. Nevertheless, the mechanistic link between the PAH and metabolic disorders remains unexplored. Mitochondrial dysfunction (MD) is one of the primary pathogenic events tightly associated with PAH and MS/ type 2 diabetes pathobiology and could play a causative role in severe metabolic perturbations. We hypothesized that dysfunctional mitochondria are sufficient to initiate metabolic rearrangements associated with PAH and classical metabolic disorders. In this study, we used the recently established rat model reproducing a human mutation in the NFU1 protein, which is responsible for mitochondrial homeostasis. NFU1G206Crats develop a severe MD and spontaneously develop PAH characterized by increased right ventricle (RV) systolic pressure, RV hypertrophy, and obliterative disease of the small pulmonary arteries. An intraperitoneal glucose tolerance test (IPGTT) was used to assess the ability of NFU1G206Crats to metabolize glucose. Plasma insulin levels were measured to control insulin sensitivity. Pulmonary arterial smooth muscle cells (PASMCs) isolated from WT and NFU1G206C rats were used for measuring fatty acid oxidation (FAO) by Seahorse palmitate‐BSA oxidation assay, mitochondria isolations, and western blot analysis. After 5 hours of fasting, WT and NFU1G206C rats had the same baseline glucose levels (glucose (mg/dL) is 89.5±2.0 vs. 92.0±6.2; p=0.47 in WT (N=5) vs. NFU1G206C(N=6)). However, 15 min after glucose administration (2 g/kg), NFU1G206Cshowed significantly higher levels of blood glucose, which reached the peak by 30 min (193.4±32.3 vs. 340.8±50.1; p<0.05 in WT vs. NFU1G206C) and remained high even after 120 min, when the glucose level of WT rats reached the baseline (96.1±11.1 vs. 155.9±15.9; p<0.02 in WT vs. NFU1G206C). MD was also sufficient to induce a significantly delayed insulin response in NFU1G206Ccompared to WT, suggesting the reduced insulin sensitivity in rats with MD. We also discovered an upregulated expression of free fatty acid (FFA) transporters, CD36 and CPT1, in NFU1G206C PASMC, which corresponded to the increased levels of basal FAO in the mutant cells. This discovery was confirmed by mitochondrial proteome analysis, revealing a significantly upregulated FA metabolism and dysregulated FA synthesis in NFU1G206C PASMC. NFU1G206C PASMC also had an increased membrane translocation of PKCα, one of the diacylglycerol‐dependent PKCs activated by FFAs and involved in reduced insulin sensitivity. We conclude that the MD secondary to the NFU1 insufficiency induces significant metabolic derangements, such as increased flux of fatty acids, glucose intolerance, and insulin insensitivity associated with classic metabolic disorders and recently implemented in the pathogenesis of PAH. The severe metabolic reprogramming revealed in PASMC correlates with progressive pulmonary vascular disease in NFU1G206Crats.

Metabolic Deregulation in Pulmonary Hypertension

Abstract 4141118: Identifying PDK4 As A Metabolic Regulator in Pulmonary Arterial Hypertension: Insights from Bulk, Single-cell Transcriptomics Analysis and Clinical Validation

Metabolic Reprogramming of the Right Ventricle and Pulmonary Arteries in a Flow-Associated Pulmonary Arterial Hypertension Rat Model

Metabolic reprogramming: A novel metabolic model for pulmonary hypertension

Metabolic Reprogramming in the Heart and Lung in a Murine Model of Pulmonary Arterial Hypertension

Metabolic Reprogramming and Redox Signaling in Pulmonary Hypertension

Mitochondrial Dysfunction Dictates Energy Metabolism Reprogramming in Pulmonary Arterial Hypertension

The Glycobiology of Pulmonary Arterial Hypertension

Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming

Transpulmonary amino acid metabolism in the sugen hypoxia model of pulmonary hypertension

Metabolic reprogramming in pulmonary arterial hypertension: is it a cancer-like disease?

Proline and glucose metabolic reprogramming supports vascular endothelial and medial biomass in pulmonary arterial hypertension

Abstract P3009: Fatty Acid-binding Proteins Promote Pulmonary Arterial Hypertension Via Upregulation Of Endothelial Glycolysis

Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension

Endothelial Cell Energy Metabolism, Proliferation, and Apoptosis in Pulmonary Hypertension

Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline

Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1

Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension

Identification of MicroRNA-124 As a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension Via PTBP1 (polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2

Metabolic reprogramming, oxidative stress, and pulmonary hypertension

Metabolomics-based Mechanism Exploration of Pulmonary Arterial Hypertension Pathogenesis: Novel Lessons from Explanted Human Lungs